-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2023-508897-27-00
5
2022-04-28
Multiple Myeloma
-
2023-509208-14-00
5
2021-09-28
MULTIPLE MYELOMA
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2023-510268-11-00
4
2019-06-11
Cervical cancer
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2024-511096-15-00
5
2014-08-01
Breast Cancer
-
2024-517622-25-00
5
2013-12-06
Patients with localized prostate cancer and high-risk features of rela
-
2023-505096-68-00
4
2025-01-14
Preclinical Alzheimer’s Disease
-
2022-502049-91-00
4
2023-09-26
SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
-
2025-521107-42-00
4
2025-11-25
Alzheimer's Disease
-
2024-514559-13-00
10
2024-11-26
Focal Epilepsy
-
2024-519275-26-00
9
2024-11-15
Newly diagnosed acute myeloid leukemia patients aged equal or more tha
-
2023-505903-22-00
4
2024-07-02
Sepsis associated acute kidney injury
-
2023-508440-21-00
5
2024-05-21
Infections due to Enterobacteriaceae
-
2023-505083-11-01
4
2024-05-07
Alzheimer's Disease
-
2023-507640-36-00
5
2024-04-29
Resistant hypertension (rHTN) defined as blood pressure that remains h
-
2022-501952-27-00
5
2024-04-19
Hospital-acquired bacterial pneumonia (HABP), including ventilated HAB
-
2023-506092-10-00
4
2024-03-11
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous